Gastrointestinal effects of NSAIDs and coxibs

Journal of Pain and Symptom Management

Volumn 25, Issue 2 SUPPL., 2003, Pages 32-40

  Laine, Loren ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Celecoxib; COX 1; COX 2; COX 2 inhibitors; Coxibs; Cyclooxygenase; Gastrointestinal; NSAIDs; Rofecoxib; Safety

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOROLAC; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SALICYLIC ACID DERIVATIVE;

CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; REVIEW; RISK FACTOR;

EID: 0037320997     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0885-3924(02)00629-2     Document Type: Review

References (43)

1. Talley N.J., Evans J.M., Fleming K.C.et al. Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 40:1995;1345-1350.
2. Laine L. Approaches to NSAID use in the high-risk patient. Gastroenterology. 120:2001;594-606.
3. O'Laughlin J.C., Hoftiezer J.W., Ivey K.J. Effect of aspirin on the human stomach in normals. endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration Scand J Gastroenterol. 16(Suppl 67):1981;211-214.
4. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am. 6:1996;489-504.
5. MacDonald T.M., Morant S.V., Robinson G.C.et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure. cohort study BMJ. 315:1997;1333-1337.
6. Hallas J., Lauritsen J., Dalsgard Villadsen H.et al. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol. 30:1995;438-444.
7. Smalley W.E., Ray W.A., Daugherty J.R.et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 141:1995;539-545.
8. Silverstein F.E., Graham D.Y., Senior J.R.et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 123:1995;241-249.
9. Silverstein F., Faich G., Goldstein J.L.et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study. a randomized controlled trial JAMA. 284:2000;1247-1255.
10. Bombardier C., Laine L., Reicin A.et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528.
11. FDA Arthritis Advisory Committee meeting. February 7, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm .
12. Derry S., Loke Y.K. Risk of gastrointestinal hemorrhage with long term use of aspirin. meta-analysis BMJ. 321(7270):2000;1183-1187.
13. Sørensen H.T., Mellemkjaer L., Blot W.J.et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 95(9 2218-2224):2000.
14. Serrano P., Lanas A., Arroyo M.T.et al. Risk stratification of upper gastrointestinal bleeding in cardiovascular patients on low-dose aspirin. A cohort study. Gastroenterology. 118:2000;A862. (abstract).
15. Weil J., Colin-Jones D., Langman M.et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 310:1995;827-830.
16. Kelly J.P., Kaufman D.W., Jurgelon J.M.et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 348:1996;1413-1416.
17. Larkai E.N., Smith J.L., Lidsky M.D.et al. Dyspepsia in NSAID users. the size of the problem J Clin Gastroenterol. 11:1989;158-162.
18. Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 28:1987;527-532.
19. Holvoet J., Terriere L., Van Hee W.et al. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin. a case control study Gut. 32:1991;730-734.
20. Bloom B.S. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med. 84(Suppl 2A):1986;20-24.
21. Smalley W.E., Griffin M.R., Fought R.L.et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med. 11:1996;461-469.
22. Lanes S.F., Lanza L.L., Radensky P.W.et al. Resource utilization and cost of care for rheumatoid arthritis in a managed care setting. The importance of drug and surgery costs. Arthritis Rheum. 40:1997;1475-1481.
23. Rahme E., Joseph L., Kong S.X.et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs versus acetaminophen. retrospective cohort study of an elderly population Arthritis Rheum. 43:2000;917-924.
24. Henry D., Lim L L.-Y., Garcia Rodriguez L.et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs. results of a collaborative meta-analysis BMJ. 312:1996;1563-1566.
25. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 115:1991;787-796.
26. Langman M.J.S., Weil J., Wainwright P.et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;1075-1078.
27. Garcia Rodriguez L.A., Cattaruzzi C., Troncon M.G.et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 158:1998;33-39.
28. Cryer B., Goldschmiedt M., Redfern J.S.et al. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology. 99:1990;1616-1621.
29. Scheiman J.M., Behler E.M., Berardi R.R.et al. Salicyl-salicylic acid causes less gastroduodenal damage than enteric-coated aspirin. an endoscopic comparison Dig Dis Sci. 34:1989;229-232.
30. Laine L., Sloane R., Ferretti M.et al. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 42:1995;428-433.
31. Taha A.S., McLaughlin S., Holland P.J.et al. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. Ann Rheum Dis. 49:1990;354-358.
32. ® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther. 21:1999;659-674.
33. Hawkey C., Kahan A., Steinbruck K.et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol. 37:1998;937-945.
34. Dequeker J., Hawkey C., Kahan A.et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam. results of the safety and efficacy large-scale evaluation of cox-inhibiting therapies (SELECT) trial in osteoarthritis Br J Rheumatol. 37:1998;946-951.
35. Kargman S., Charleson S., Cartwright M.et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 111:1996;445-454.
36. ™, MK-0966, 4-(4"methylsulfonyl)-3-phenyl-2-(5H)-furanone). a potent, selective and orally active cyclooxygenase-2 inhibitor - pharmacological and biochemical profiles J Pharmacol Exp Ther. 290:1999;551-560.
37. McAdam B.F., Catella-Lawson F., Mardini I.A.et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2. the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci. 96:1999;272-277.
38. Ehrich E.W., Dallob A., De Lepeleire I.et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 65:1999;336-347.
39. Laine L., Harper S., Simon T.et al. A randomized trial comparing the effect of rofecoxib, a COX-2 specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients. Gastroenterology. 117:1999;776-783.
40. Hawkey C., Laine L., Simon T.et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 43:2000;370-377.
41. Simon L.S., Weaver A.L., Graham D.Y.et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA. 282:1999;1921-1928.
42. Emery P., Zeidler H., Kvien T.K.et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis. randomized double-blind comparison Lancet. 354:1999;2106-2111.
43. Singh G., Goldstein J., Bensen W.et al. SUCCESS-1 in osteoarthritis (OA) trial. Celecoxib significantly reduces risk of serious upper GI complications compared to NSAIDs while providing similar efficacy in 13,274 randomized patients Ann Rheum Dis. 60(Suppl 1):2001;58.